文献速递骨质疏松与代谢性骨病创伤骨科

正常范围促甲状腺激素与绝经后女性骨小梁评分及5年骨折风险相关

Thyroid-stimulating hormone is associated with trabecular bone score and 5-year incident fracture risk in euthyroid postmenopausal women: the OsteoLaus cohort.
PubMed 文献 · Osteoporos Int · 2021-08-19

结果显示,正常范围内TSH与腰椎骨小梁评分(TBS)呈正相关,与5年主要骨质疏松性骨折风险呈负相关,但与骨密度(BMD)无显著关联。

要点

  • 甲状腺功能正常的绝经后女性中,TSH与TBS独立正相关。
  • TSH与5年主要骨质疏松性骨折风险负相关,fT4无此关联。
  • TSH与腰椎、股骨颈及全髋BMD均无显著关联。

核心结论

  • 在甲状腺功能正常的绝经后女性中,正常范围内TSH水平与TBS正相关,与5年主要骨质疏松性骨折风险负相关,而不影响BMD。

研究设计与样本

  • 纳入标准排除了使用抗骨质疏松药、抗糖尿病药、甲状腺调节药、激素替代治疗或全身性糖皮质激素的女性。
  • 基线评估腰椎、股骨颈及全髋BMD、腰椎TBS及椎体骨折,5年后通过问卷和DXA评估新发主要骨质疏松性骨折。

主要发现

  • TSH或fT4与任何部位BMD均无显著关联。
  • TSH与TBS呈正相关(β = 0.138,p < 0.01),校正年龄、BMI及绝经年限后仍显著(β = 0.086,p < 0.05)。
  • 5年随访后,发生主要骨质疏松性骨折的女性TSH水平低于未骨折者(1.77 ± 0.13 vs. 2.05 ± 0.04 mU/l,p < 0.05),fT4无差异。

关键数值与推荐

  • TSH与TBS的未校正回归系数β = 0.138(p < 0.01),校正后β = 0.086(p < 0.05)。
  • 骨折组与非骨折组TSH分别为1.77 ± 0.13 mU/l和2.05 ± 0.04 mU/l(p < 0.05)。

临床怎么用

  • 在甲状腺功能正常的绝经后女性中,评估骨折风险时除BMD外可关注TSH水平及TBS。
  • 正常范围内较低的TSH可能提示骨微结构受损及骨折风险增加,需进一步研究验证干预价值。

局限性

  • 原文未报告局限性描述。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: Thyroid-stimulating hormone (TSH) excess or deficiency influences bone density and fracture risk. Nevertheless, does TSH in the reference range influence bone health? In euthyroid postmenopausal women, TSH levels in the reference range were positively associated with trabecular bone score and negatively with incident fractures, without affecting BMD. PURPOSE: Subclinical hyperthyroidism is associated with low bone mineral density (BMD) and increased fracture risk. In healthy postmenopausal women, association between thyroid-stimulating hormone (TSH) in the normal range and BMD is contradictory. Trabecular bone score (TBS), an index of bone micro-architecture, is often decreased in secondary osteoporosis (OP). The aim was to determine the association between thyroid hormones (TSH, fT4) and BMD, TBS, and the incident 5-year OP fractures, in euthyroid post-menopausal women. METHODS: We assessed 1475 women of the CoLaus/OsteoLaus cohort. We evaluated BMD at lumbar spine, femoral neck and total hip, lumbar spine TBS, and vertebral fracture with DXA. Incident major OP fractures were evaluated 5 years later by questionnaire and DXA. Women with anti-osteoporotic, antidiabetic, thyroid-modifying, hormone replacement, or systemic corticoid treatment were excluded. RESULTS: Five hundred thirty-three women (age 68.4 ± 7.3 years, BMI 25.9 ± 4.6 kg/m2, TSH 2.03 ± 0.87 mU/l, fT4 15.51 ± 1.85 pmol/l) met the inclusion criteria. There was no significant association between TSH or fT4 and BMD measures at any site. A positive association was found between TSH and TBS (β = 0.138, p < 0.01), even after adjusting for age, BMI, and duration of menopause (β = 0.086, p < 0.05). After a 5-year follow-up, women with incident major OP fractures had lower TSH levels (1.77 ± 0.13 vs. 2.05 ± 0.04 mU/l, p < 0.05) than women without fractures, while no difference was found for fT4. CONCLUSION: In euthyroid postmenopausal women, TSH levels were positively associated with TBS and negatively with incident fractures, without affecting BMD. Further studies are needed to evaluate the influence of thyroid hormones on TBS.

来源:Osteoporos Int,查看原文。版权归原作者所有。

引用

  1. Vendrami C, Marques-Vidal P, Gonzalez Rodriguez E, et al. Thyroid-stimulating hormone is associated with trabecular bone score and 5-year incident fracture risk in euthyroid postmenopausal women: the OsteoLaus cohort. Osteoporos Int. 2021. PMID: 34409507. doi:10.1007/s00198-021-06081-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。